ABSTRACT. Mutations of Fas (CD95/Apo-
Fas (CD95/Apo-1) is a cell-surface receptor in a major signaling pathway for the induction of apoptosis, and a member of the death receptor subfamily of tumor necrosis factor receptor superfamily [7, 23, 28] . Mice bearing germline mutation of the Fas gene (MRL-MpJ/Fas lpr mouse) have an abnormality of mature T-cell deletion in the peripheral tissues resulting in lymphadenopathy, splenomegaly and systemic autoimmune disease [1, 25, 26] . Mutations of the Fas gene have been reported in lymphoid-lineage malignancies [2, 5, 12, 21, 24] , myeloid tumor [8] , and non-small cell lung cancer [3, 9] , and suppression of Fas gene expression has been observed in esophageal cancer [4] . Germline mutations of the Fas gene in humans are also associated with a high risk of both lymphoid and solid tumors [13] . Therefore, the Fas gene has been considered to be a tumor suppressor gene.
On the other hand, loss of heterozygosity (LOH) has been reported in numerous neoplasms in both humans and laboratory animals, and has often been observed in chromosomal regions containing tumor suppressor genes [10, 27] . One allele of the recessive tumor suppressor genes is often inactivated by methylation or small mutations such as base substitutions or microdeletions. The function of the other wildtype allele has been thought to be subsequently lost by chromosomal rearrangements, e.g. deletion, mitotic recombination, and nondisjunction which can be detected by LOH. Therefore, LOH studies have been performed to detect the secondary event, that is, the loss of remaining alleles of recessive tumor suppressor genes responsible for tumorigenesis. Several putative tumor suppressor regions have been reported in radiation-induced lymphomas from mice [11, 17, 18, 20, 22] . In some F 1 mice, allelic loss on chromosome 19 containing a Fas locus is observed [18, 22] . In this study, we examined the LOH in lymphomas from MRL-MpJ/Fas lpr (MRL-lpr) mice were obtained from Nihon Clear Co.. MSM/Ms (MSM) and BALB/cHeA (BALB/c) mice were described previously [16] . The breeding conditions were described previously [19] . (M × lpr) F 1 and (C × lpr)F 1 hybrid mice were exposed to X-rays at 2.5 Gy or 1.7 Gy (0.5 Gy/min), respectively, four times at weekly intervals starting at 4 weeks of age. The dose of Xrays was increased in (M × lpr) F 1 mice more than in (C × lpr)F 1 hybrid mice because the MSM mice are considerably more resistant to radiation lymphomagenesis than BALB/c mice [16] . The mice were observed for 1 year after the last irradiation at 7 weeks old (One year after the last irradiation corresponds to 414 days after birth). The moribund mice were examined as previously described [15] . All animal experiments were carried out in accordance with the Standards Relating to the Care and Management of Experimental Animals (Japan) and the Guidelines for Animal Care and Use of Osaka Prefecture University.
Fifty-three female and 53 male of (M × lpr) F 1 hybrid mice were irradiated with four 2.5 Gy doses as described above. Lymphoma development was clearly observed in the irradiated F 1 hybrids (Fig. 1A) . Within 1 year after the last irradiation (414th day after birth), 26 females and 28 males developed lymphomas. The cumulative incidences of the tumors were 53% (28/53) in females and 49% (26/53) in males. All the lymphomas were typical malignant thymic lymphomas on pathological examination. In contrast, 12 non-irradiated females and 10 males had developed no lym-* PRESENT ADDRESS: OGAWA, S., Sumitomo Pharmaceutical Co., **CORRESPONDENCE TO: OKUMOTO, M., Research Institute for Advanced Science and Technology, Osaka Prefecture University, 1-2 Gakuen-cho, Sakai, Osaka 599-8570, Japan.
phoma by the 414th day after birth. Fifty-two females and 51 males of the other F 1 mice, (C × lpr) F 1 , were irradiated with four 1.7 Gy doses. By 1 year after the last irradiation, 37 females and 32 males had developed the lymphomas (Fig. 1B) . Cumulative incidences of the tumors are 71% (37/52) in females and 63% (32/51) in males. All the lymphomas were also typical malignant thymic lymphomas. Thirteen non-irradiated females and 12 males had developed no lymphoma by 414 days after birth. These radiation-induced malignant tumors were used in the following allelotype analyses.
Developed lymphomas and normal tissues were removed )F 1 hybrid mice were exposed to 1.7 Gy (0.5 Gy/min) X-rays, four times at weekly intervals starting at 4 weeks of age.
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for DNA isolation. DNA isolation, PCR of the microsatellite marker, electrophoresis of PCR products and assessment of allelic losses were performed according to the procedure described previously [17] . Oligonucleotide primers corresponding to microsatellite loci were purchased from Research Genetics, Inc. (Huntsville, AL). Chromosomal locations of the microsatellite markers and several loci were according to the 2000 Chromosome Committee Reports in Mouse Genome Informatics (Jackson Laboratory, Bar Harbor, ME). The wild-type Fas gene sequence in intron 2 into which the early transposable element (ETn) is inserted in lpr mice, were amplified with recombinant Taq DNA polymerase (Takara Shuzo Co., Ltd., Shiga, Japan).
LOH analysis was first carried out for 24 thymic lymphomas from (M × lpr) F 1 mice at 73 polymorphic microsatellite loci (Table 1A) . Frequent LOH (16/24, 67%) was observed at D12Mit279 (53 cM). LOH with a lower incidence was also observed in several loci; five of 24 lymphomas (21%) had LOH at D4Mit31 (51.3 cM), and 4 lymphomas (16%) at D4Mit9 (44.5cM) and D4Mit4 (12.1cM); two lymphomas (8%) at D2Mit51 (95.5 cM), and two other lymphomas at D16Mit74 (9.7 cM); one (4%) at D3Mit17 (71.8 cM) and another one at D14Mit97 (58 cM). No allelic loss was observed on chromosome 19 containing a Fas locus. As frequent LOH was observed on chromosome 12, the LOH region was carefully examined with additional markers on the chromosome and 51 tumors. A highly frequent peak was observed at D12Mit279 (53 cM), and the frequency was 71% (36/51) (Fig. 2) . This region seems to be the same region as that of the highest frequency of LOH observed in (BALB/c × MSM)F 1 mouse lymphomas [11, 17] , and is syntenic homologous to human chromosome 14q32-33 at which frequent LOH has been reported in a variety of human cancers. LOH survey was also carried out for 12 or 13 thymic lymphomas from (C × lpr) F 1 mice at 56 polymorphic microsatellite loci (Table 1B) . As found in the tumors from (M × lpr) F 1 mice, frequent LOH was also found on chromosome 12. The loss region was refined with more markers and tumors. A peak was also found at D12Mit279, and the frequency was 55% (23/42) (Table 1B) . A low incidence of LOH was observed on chromosomes 4, 6 and 16. No allelic loss was observed on other chromosomes including chromosome 19 containing a Fas locus. Therefore, the frequent LOH region on chromosome 12 might play a major role in the lymphomagenesis of both (M × lpr) F 1 and (C × lpr) F 1 mice, whereas the Fas locus on chromosome 19 probably does not play an important role.
As mentioned above, the 2nd step in the inactivation of tumor suppressor genes can be usually detected by loss of the remaining wild-type allele. In p53-heterozygous deficient mice, almost all p53 wild-type alleles are selectively lost in lymphomas which show allelic loss on chromosome 11 containing the p53 gene [6, 14] . To examine the status of the wild-type allele of the Fas gene in tumors, we carried out PCR analysis with F-primer, GTAAATAATTGTGCT-TCGTCAG, and R-primer, CAAATCTAGGCATTAA-CAGTG [1] in 51 lymphomas from (M × lpr)F 1 mice. Wildtype alleles were retained in all the lymphomas (data not shown). This suggests that chromosomal rearrangement involving Fas did not occur as the second step inactivation of heterozygously inactivated Fas. These results in Fas-heterozygous deficient mice do not suggest that the Fas gene is predominantly involved as a tumor suppressor gene in radiation lymphomagenesis. 
